TREATMENT OUTCOMES OF ANEMIA AFTER VITAMIN B12 SUPPLEMENTATION IN END-STAGE CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING REGULAR DIALYSIS
Main Article Content
Abstract
Objective: To evaluate the treatment outcomes of anemia by erythropoietin therapy after vitamin B12 supplementation in patients with end-stage chronic kidney disease undergoing regular dialysis with vitamin B12 deficiency at Bac Lieu General Hospital. Materials and methods: A non-controlled interventional study conducted on 42 patients with end-stage chronic kidney disease undergoing regular dialysis at Bac Lieu General Hospital from July 2023 to February 2024. Results: The average age was 49.38 ± 15.21 years, with two-thirds of the patients being under 60 years old. The male-to-female ratio was 1.62. All patients had hypertension, and 16.7% had diabetes. The average duration of dialysis was 66.0 ± 42.8 months. Vitamin B12 levels significantly improved after 3 months of intervention (884.9±344.6 compared to 251.7±35.4, p<0.001). Anemia parameters, including red blood cell count (3.54±0.54 compared to 3.14±0.63, p <0.001) and hemoglobin (Hb) levels (9.08±1.61 compared to 10.4±1.67, p <0.000), also showed significant improvement after 3 months of treatment. The values of MCV, MCH, and MCHC after treatment showed no statistically significant differences. Additionally, the EPO dose was reduced after the intervention, with an average difference of -2047.6±3601.9, p=0.001. Conclusion: Vitamin B12 supplementation may contribute to improved anemia treatment by eryhtropoietin therapy in patients with end-stage chronic kidney disease undergoing regular dialysis.
Article Details
Keywords
vitamin B12 supplementation, anemia treatment, end-stage chronic kidney disease, regular dialysis.
References


2. Santos E.J.F., Dias R.S.C., Lima J.F.B., Salgado Filho N., Miranda Dos Santos A. Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives. International journal of nephrology and renovascular disease. 2020; 13. 231-237. doi:10. 2147/ijnrd.s239151.


3. Tấn Thông H., Thanh Hiệp N., Quỳnh Trúc N. Tỉ lệ thiếu máu trên bệnh nhân bệnh thận mạn đang lọc máu chu kỳ có điều trị erythropoietin và một số yếu tố liên quan tại bệnh viện nhân dân gia định, năm 2022. Tạp chí Y học Việt Nam. 2022; 514(1). doi:10.51298/vmj.v514i1.2536.


4. F. Nahas A.R.M., Al Zarzour R.H., Abu Laila A.S.M., Tabash A.M., Abu Mustafa A.M., et al. Effect of B12 supplementation on renal anemia among hemodialysis patients at El-Najar hospital, Gaza strip. J Renal Inj Prev. 0. -. doi:10. 34172/jrip.2022.32009.


5. Saifan C., Samarneh M., Shtaynberg N., Nasr R., El-Charabaty E., et al. Treatment of confirmed B12 deficiency in hemodialysis patients improves Epogen® requirements. International journal of nephrology and renovascular disease. 2013; 6. 89-93. doi:10.2147/ijnrd.s44660.

